SLC5A2 and type 2 diabetes mellitus: According to the findings of one study, patients with T2DM who took SGLT2 inhibitors were at an increased risk for developing acute kidney injury (AKI), particularly when the drugs were combined with non-steroidal anti-inflammatory drugs (NSAIDs), anti-Ras, or diuretics [15].